Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

744 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma.
Shirazi F, Jones RJ, Singh RK, Zou J, Kuiatse I, Berkova Z, Wang H, Lee HC, Hong S, Dick L, Chattopadhyay N, Orlowski RZ. Shirazi F, et al. Among authors: jones rj. Proc Natl Acad Sci U S A. 2020 Aug 18;117(33):20004-20014. doi: 10.1073/pnas.2005052117. Epub 2020 Aug 3. Proc Natl Acad Sci U S A. 2020. PMID: 32747568 Free PMC article.
Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191.
Ni H, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Hitoshi Y, Ansell SM, Treon SP, Thomas SK, Lee HC, Wang Z, Davis RE, Orlowski RZ. Ni H, et al. Among authors: jones rj. Clin Cancer Res. 2018 Dec 15;24(24):6408-6420. doi: 10.1158/1078-0432.CCR-17-3265. Epub 2018 Aug 20. Clin Cancer Res. 2018. PMID: 30126942 Free PMC article.
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Kuhn DJ, et al. Among authors: jones rj. Blood. 2012 Oct 18;120(16):3260-70. doi: 10.1182/blood-2011-10-386789. Epub 2012 Aug 29. Blood. 2012. PMID: 22932796 Free PMC article.
Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia.
Kuiatse I, Baladandayuthapani V, Lin HY, Thomas SK, Bjorklund CC, Weber DM, Wang M, Shah JJ, Zhang XD, Jones RJ, Ansell SM, Yang G, Treon SP, Orlowski RZ. Kuiatse I, et al. Among authors: jones rj. Clin Cancer Res. 2015 Jun 1;21(11):2538-45. doi: 10.1158/1078-0432.CCR-14-1462. Epub 2015 Mar 6. Clin Cancer Res. 2015. PMID: 25748087 Free PMC article.
Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma.
Zhang X, Lee HC, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Singh RK, Lu J, Qian Y, Raina K, Coleman KG, Crews CM, Li B, Wang H, Hailemichael Y, Thomas SK, Wang Z, Davis RE, Orlowski RZ. Zhang X, et al. Among authors: jones rj. Leukemia. 2018 Oct;32(10):2224-2239. doi: 10.1038/s41375-018-0044-x. Epub 2018 Mar 27. Leukemia. 2018. PMID: 29581547 Free PMC article.
The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance.
Zou J, Jones RJ, Wang H, Kuiatse I, Shirazi F, Manasanch EE, Lee HC, Sullivan R, Fung L, Richard N, Erdman P, Torres E, Hecht D, Lam I, McElwee B, Chourasia AH, Chan KWH, Mercurio F, Stirling DI, Orlowski RZ. Zou J, et al. Among authors: jones rj. J Mol Med (Berl). 2020 Aug;98(8):1161-1173. doi: 10.1007/s00109-020-01943-6. Epub 2020 Jul 6. J Mol Med (Berl). 2020. PMID: 32632752 Free PMC article.
744 results